Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SuMILE Trial: Sotatercept Add-on vs Standard Pulmonary Vasodilator Therapy in Pulmonary Vasodilator-resistant PAH with Unrepaired Congenital Shunts
jRCT1071250069Recruiting
- Sponsor
- Grants-in-Aid for Scientific Research (C)
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in pulmonary arterial hypertension (PAH), Eisenmenger syndrome and congenital heart disease-associated pulmonary hypertension (CHD-PAH) comparing Sotatercept add-on plus standard of care with Standard of care alone (2 arms). Started Nov 2025; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)Eisenmenger syndromecongenital heart disease-associated pulmonary hypertension (CHD-PAH)
Beyond the preview
Go deeper on jRCT1071250069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071250069.